Click here to buy the human growth hormone product recommended by EternalHGH.com.
Seikaly MG, Waber P, Warady BA, Stablein D
University of Texas
Southwestern Medical Center
Pediatr Nephrol. 2009 Apr 23
The
purpose of this review was to evaluate the impact of recombinant human growth
hormone (rhGH) therapy on height velocity (HV), estimated glomerular filtration
rate (eGFR) and body mass index (BMI) in children with chronic kidney disease
(CKD).
The reviewers examined longitudinal data from patients enrolled in
the chronic renal insufficiency registry of the North American Pediatric Renal
Trials and Collaborative Studies (NAPRTCS). 11.5% of the 7189 patients enrolled
in the registry had received rhGH.
The review included 787 children with
CKD who received rhGH for 1-4 years. They were paired with 787 control patients,
matched for age, gender, height and length of time in the NAPRTCS registry. The
pairs were compared for HV, eGFR and BMI. Height velocity was also compared to
the general U.S. population.
The group treated with recombinant human
growth hormone had a significantly greater height velocity standard deviation
score (SDS) than the control group at each 6-months post-rhGH treatment
initiation point for 2.5 years. Among 220 pairs at 2 years, the height SDS of
the rhGH group was 0.56 SDS higher than that of the control group. Treatment
with rhGH had no significant impact on the BMI or eGFR.
The review
concluded that recombinant human growth hormone therapy is associated with
improved height velocity in children with chronic kidney disease, but it does
not appear to have any impact on BMI or kidney function.
Start your all natural hGH supplemementation today. Click here to get started.
Hgh Research Paper Index
HGH Articles